Bridgewater Associates LP Makes New Investment in Moderna, Inc. (NASDAQ:MRNA)

Bridgewater Associates LP bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 605,782 shares of the company's stock, valued at approximately $25,188,000. Bridgewater Associates LP owned 0.16% of Moderna at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRNA. Canada Post Corp Registered Pension Plan bought a new position in Moderna during the 4th quarter worth $194,000. Lansdowne Partners UK LLP bought a new position in shares of Moderna in the fourth quarter worth $1,455,000. Townsquare Capital LLC raised its stake in Moderna by 14.2% in the fourth quarter. Townsquare Capital LLC now owns 6,040 shares of the company's stock valued at $251,000 after purchasing an additional 752 shares in the last quarter. Quinn Opportunity Partners LLC bought a new stake in Moderna during the fourth quarter worth about $686,000. Finally, Treasurer of the State of North Carolina grew its stake in Moderna by 3.8% during the fourth quarter. Treasurer of the State of North Carolina now owns 206,884 shares of the company's stock worth $8,602,000 after buying an additional 7,490 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Citigroup initiated coverage on shares of Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 price target for the company. Leerink Partners lowered their price target on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. Bank of America reduced their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a research note on Tuesday, February 11th. Morgan Stanley dropped their target price on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a report on Wednesday, April 9th. Finally, Evercore ISI set a $50.00 target price on shares of Moderna in a research report on Friday, February 14th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $58.70.

Moderna Stock Down 0.1 %

Moderna stock traded down $0.02 during trading hours on Monday, reaching $24.70. 2,340,377 shares of the company's stock were exchanged, compared to its average volume of 7,269,165. The firm's 50 day simple moving average is $30.84 and its 200 day simple moving average is $39.49. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $170.47. The firm has a market capitalization of $9.55 billion, a PE ratio of -2.66 and a beta of 2.23.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.